Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size

Stroke

Volumn 29, Issue 5, 1998, Pages 1020-1030

  Romanic, Anne M ^a   White, Raymond F ^a   Arleth, Anthony J ^a   Ohlstein, Eliot H ^a   Barone, Frank C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antibody inhibition; Blood brain barrier; Endothelium, vascular; Leukocytes; Metalloproteinases; Neutrophils; Stroke, ischemic

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0031959973     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.5.1020     Document Type: Article

References (37)

1. Yurchenko PD, Schittney JC. Molecular architecture of the basement membrane. FASEB J. 1990;4:1577-1590.
2. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
3. Matresian LM. The matrix-degrading metalloproteinases. Bioessays. 1992;14:455-463.
4. Romanic AM, Madri JA. Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol. 1994;4:145-156.
5. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94: 2493-2503.
6. Galis ZS, Sukhova GK, Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J. 1995;9:974-980.
7. Romanic AM, Madri JA. The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. J Cell Biol. 1994;125:1165-1178.
8. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol. 1996;156:1-4.
9. Liotta L., Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980;284:67-68.
10. 1 integrins during human melanoma cell invasion. Cancer Res. 1993;53:3411-3415.
11. Crawford HC, Matresian LM. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis. 1995:14:234-245.
12. Risau W, Wolburg H. Development of the blood-brain barrier. Trends Neurosci. 1990;13:174-178.
13. Robert AM, Godeau G. Action of proteolytic and glycolytic enzymes on the permeability of the blood-brain barrier. Biomedicine. 1974;21:36-39.
14. Rosenberg GA. Matrix metalloproteinases in brain injury. J Neurotrauma. 1995;12:833-842.
15. Koroshefz WJ, Moskowitz MA. Emerging treatments for stroke in humans. Trends Pharmacol Sci. 1996;17:227-233.
16. Seisjö BK. Mechanisms of ischemic brain damage. Crit Care Med. 1988;16:954-963.
17. Rosenberg GA, Dencoff JE, McGuire PG, Liotta LA, Stetler-Stevenson WG. Injury-induced 92-kilodalton gelatinase and urokinase expression in rat brain. Lab Invest. 1994;71:417-422.
18. Rosenberg GA, Navratil M, Barone F, Feuerstein GZ. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab. 1996;16:360-366.
19. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke. 1995;26:2120-2126.
20. Clark RK, Lee EV, Fish CJ, White RF, Price WJ, Jonak ZL, Feuerstein GZ, Barone FC. Development of tissue damage, inflammation and resolution following stroke: an immunohistochemical and quantitative planimetric study. Brain Res Bull. 1993;31:565-572.
21. Barone FC, Hillegass LM, Tzimas MN, Schmidt DB, Foley JJ, White RF, Price WJ, Feuerstein GZ, Clark RK, Griswold DE, Sarau HM. Time-related changes in myeloperoxidase activity and leukotriene by receptor binding reflect leukocyte influx in cerebral focal stroke. Mol Chem Neuropathol. 1995;24:13-30.
22. Matsuo Y, Onodera H, Shiga Y, Nalcamur M, Ninomiya M, Kihara T, Kogure K. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat: effects of neutrophil depletion. Stroke. 1994;25:1469-1475.
23. Weiss SJ, Peppin GJ. Collagenolytic metalloenzymes of the human neutrophil. Biochem Pharmacol. 1986;35:3189-3197.
24. Barone FC, Price WJ, White RF, Willette RN, Feuerstein GZ. Genetic hypertension and increased susceptibility to cerebral ischemia. Neurosci Biobehav Rev. 1992;16:219-233.
25. Laemmli UK. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature. 1970;227:680-685.
26. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells. J Biol Chem. 1986;261:2814-2818.
27. Ramos-DeSimone N, Moll UM, Quigley JP, French DL. Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody. Hybridoma. 1993;12:349-363.
28. Bederson JB, Pitts LH, German SM, Nishimura MC, Davis RL, Bartowski HM. Evolution of 2,3,5-triphenyl tetrazolium chloride as a stain for detection and quantitation of experimental cerebral infarction in rats. Stroke. 1986;17:1304-1308.
29. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab. 1990;10:290-293.
30. Lin T-N, He YY, Wu G, Khan M, Hsu CY. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke. 1993;24:117-121.
31. Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, Lysko PG, Feuerstein GZ. Tumor necrosis factor-α: a mediator of focal ischemic brain injury. Stroke. 1997;28:1233-1244.
32. Unemori EN, Bouhana KS, Werb Z. Vectoral secretion of extracellular matrix proteins, matrix-degrading proteinases, and tissue inhibitor of metalloproteinases by endothelial cells. J Biol Chem. 1990;265:445-451.
33. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem. 1992;267:3581-3584.
34. Ogata Y, Itoh Y, Nagase H. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem. 1994;270:18506-18511.
35. Liotta LA, Steeg PC, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327-336.
36. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke. 1992;23:1367-1379.
37. Clements JM, Cossins JA, Wells GMA, Corkill DJ, Helfrich K, Wood LM, Pigott R, Stabler G, Ward GA, Gearing AJH, Miller KM. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumor necrosis factor-α inhibitor. J Neuroimmunol. 1997;47:85-94.